← All trials
NCT04970901
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Dec 30, 2021
- Primary completion
- Feb 12, 2025
- Completion date
- Feb 10, 2026
- First posted
- Jul 21, 2021
- Last posted
- Nov 29, 2021
- Enrollment
- 200
- Arms / groups
- 8 / —
- Source
- AACT · ingestion pipeline
Sponsors
- ADC Therapeutics SARLLead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.